Download PDF
Semin Thromb Hemost 2015; 41(02): 160-165
DOI: 10.1055/s-0035-1544157
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Venous Thromboembolism with New Oral Anticoagulants According to Patient Risk

Sam Schulman
1   Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
2   Department of Medicine, Karolinska Institutet, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Publication Date:
15 February 2015 (online)

    Permissions and Reprints

Abstract

Recent developments in antithrombotic therapy have provided us with choices between unfractionated heparin, low-molecular-weight heparin (LMWH), vitamin K antagonists (VKA), and inhibitors against factor Xa or against thrombin for the management of venous thromboembolism. The factors that influence our decision should be efficacy, safety, convenience, and, when there is weak evidence, also patient values and preferences. The available options have largely similar efficacy, the documented exception being LMWH as superior to VKA in patients with active cancer. For the majority of patients we have today strong evidence regarding safety from large randomized trials, but this does not apply to many of the subsets of patients. In this review the choice of treatment is focused on the risks that are known or can be predicted for the individual patient. Three principal decision points on how to tailor the therapy individually are discussed—at diagnosis, for hospitalized patients at the time of discharge and finally after 3 to 6 months.

Keywords

venous thromboembolism - factor Xa inhibitors - thrombin inhibitors - vitamin K antagonists - heparin - bleeding
 

  • References

  • 1 Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI ; American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl): 141S-159S
    CrossrefPubMedGoogle Scholar
  • 2 Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN ; Fragmin-Study Group. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71 (6) 698-702
    PubMedGoogle Scholar
  • 3 Koopman MM, Prandoni P, Piovella F , et al; The Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334 (11) 682-687
    CrossrefPubMedGoogle Scholar
  • 4 Levine M, Gent M, Hirsh J , et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334 (11) 677-681
    CrossrefPubMedGoogle Scholar
  • 5 Aujesky D, Roy PM, Verschuren F , et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011; 378 (9785) 41-48
    CrossrefPubMedGoogle Scholar
  • 6 Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994; 271 (3) 223-225
    CrossrefPubMedGoogle Scholar
  • 7 Nielsen HK, Husted SE, Krusell LR, Fasting H, Charles P, Hansen HH. Silent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. J Intern Med 1994; 235 (5) 457-461
    CrossrefPubMedGoogle Scholar
  • 8 Schulman S, Lindmarker P, Holmström M , et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4 (4) 734-742
    CrossrefPubMedGoogle Scholar
  • 9 Lecumberri R, Alfonso A, Jiménez D , et al; RIETE investigators. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thromb Haemost 2013; 110 (4) 834-843
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Aujesky D, Obrosky DS, Stone RA , et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172 (8) 1041-1046
    CrossrefPubMedGoogle Scholar
  • 11 Aujesky D, Perrier A, Roy PM , et al. Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism. J Intern Med 2007; 261 (6) 597-604
    CrossrefPubMedGoogle Scholar
  • 12 Jiménez D, Aujesky D, Moores L , et al; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170 (15) 1383-1389
    CrossrefPubMedGoogle Scholar
  • 13 Zondag W, Vingerhoets LM, Durian MF , et al; Hestia Study Investigators. Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function. J Thromb Haemost 2013; 11 (4) 686-692
    CrossrefPubMedGoogle Scholar
  • 14 Agnelli G, Buller HR, Cohen A , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (9) 799-808
    CrossrefPubMedGoogle Scholar
  • 15 Bauersachs R, Berkowitz SD, Brenner B , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 16 Büller HR, Prins MH, Lensin AW , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 17 Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008; 122 (6) 743-752
    CrossrefPubMedGoogle Scholar
  • 18 Kearon C, Akl EA, Comerota AJ , et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e419S-e494S
    CrossrefPubMedGoogle Scholar
  • 19 Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144 (9) 673-684
    CrossrefPubMedGoogle Scholar
  • 20 Schulman S, Beyth RJ, Kearon C, Levine MN ; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl): 257S-298S
    CrossrefPubMedGoogle Scholar
  • 21 Casserly LF, Dember LM. Thrombosis in end-stage renal disease. Semin Dial 2003; 16 (3) 245-256
    CrossrefPubMedGoogle Scholar
  • 22 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1) 31-41
    Google Scholar
  • 23 Kearon C, Ginsberg JS, Julian JA , et al; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296 (8) 935-942
    CrossrefPubMedGoogle Scholar
  • 24 Lee AY, Levine MN, Baker RI , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (2) 146-153
    CrossrefPubMedGoogle Scholar
  • 25 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
    CrossrefPubMedGoogle Scholar
  • 26 Heit JA, O'Fallon WM, Petterson TM , et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162 (11) 1245-1248
    CrossrefPubMedGoogle Scholar
  • 27 Rahme E, Feugère G, Sirois C, Weicker S, Ramos E. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study. Thromb Res 2013; 131 (3) 210-217
    CrossrefPubMedGoogle Scholar
  • 28 Schulman S, Eriksson H, Goldhaber SZ , et al. Influence of renal function on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-Cover and RE-Cover II. Blood 2013; 122 (21) 212
    PubMedGoogle Scholar
  • 29 Schulman S, Eriksson H, Goldhaber SZ , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-Cover and RE-Cover II. Blood 2013; 122 (21) 2375
    PubMedGoogle Scholar
  • 30 Agnelli G, Buller HR, Cohen A , et al; PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (8) 699-708
    CrossrefPubMedGoogle Scholar
  • 31 Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost 2011; 105 (2) 245-253
    PubMedGoogle Scholar
  • 32 Granger CB, Alexander JH, McMurray JJ , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 33 Connolly SJ, Eikelboom J, Joyner C , et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (9) 806-817
    CrossrefPubMedGoogle Scholar
  • 34 Zhang D, Frost CE, He K , et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab Dispos 2013; 41 (4) 906-915
    CrossrefPubMedGoogle Scholar
  • 35 Rodger MA, Kahn SR, Wells PS , et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179 (5) 417-426
    CrossrefPubMedGoogle Scholar
  • 36 Schulman S, Kearon C, Kakkar AK , et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (8) 709-718
    CrossrefPubMedGoogle Scholar
  • 37 Connolly SJ, Wallentin L, Ezekowitz MD , et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation 2013; 128 (3) 237-243
    CrossrefPubMedGoogle Scholar